- Home
- INSM vs IR Comparison
INSM vs IR Comparison
Compare INSM & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- IR
- Stock Information
- Founded
- INSM 1988
- IR 1859
- Country
- INSM United States
- IR United States
- Employees
- INSM N/A
- IR N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- IR Industrial Machinery/Components
- Sector
- INSM Health Care
- IR Industrials
- Exchange
- INSM Nasdaq
- IR Nasdaq
- Market Cap
- INSM 26.0B
- IR 31.1B
- IPO Year
- INSM 2000
- IR N/A
- Fundamental
- Price
- INSM $145.10
- IR $81.02
- Analyst Decision
- INSM Strong Buy
- IR Buy
- Analyst Count
- INSM 19
- IR 10
- Target Price
- INSM $142.38
- IR $98.70
- AVG Volume (30 Days)
- INSM 3.0M
- IR 2.4M
- Earning Date
- INSM 10-30-2025
- IR 10-30-2025
- Dividend Yield
- INSM N/A
- IR 0.10%
- EPS Growth
- INSM N/A
- IR N/A
- EPS
- INSM N/A
- IR 1.29
- Revenue
- INSM $398,105,000.00
- IR $7,364,300,000.00
- Revenue This Year
- INSM $32.47
- IR $8.22
- Revenue Next Year
- INSM $126.03
- IR $5.35
- P/E Ratio
- INSM N/A
- IR $62.64
- Revenue Growth
- INSM 21.15
- IR 4.67
- 52 Week Low
- INSM $60.40
- IR $65.61
- 52 Week High
- INSM $146.84
- IR $106.03
- Technical
- Relative Strength Index (RSI)
- INSM 79.86
- IR 52.56
- Support Level
- INSM $128.02
- IR $76.87
- Resistance Level
- INSM $146.84
- IR $81.49
- Average True Range (ATR)
- INSM 3.66
- IR 1.69
- MACD
- INSM 0.71
- IR 0.26
- Stochastic Oscillator
- INSM 91.65
- IR 89.63
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.